Mesoblast delivered US$115 million in Ryoncil® revenue in its first full year post-FDA approval, while expanding clinical trials into adult indications and acquiring cutting-edge CAR technology to boost its cell therapy pipeline.
- Ryoncil® nets US$36 million in Q4 and US$115 million full-year revenue
- Adult steroid-refractory acute GvHD trial underway with 40 US sites
- Phase 3 chronic low back pain trial reaches 300-patient target
- US$50 million drawn from five-year facility to retire maturing debt
- Exclusive license acquired for CAR platform to enhance MSC therapies
Ryoncil® Revenue Milestone and Expansion Strategy
Mesoblast Limited (ASX:MSB) marked a significant commercial milestone with Ryoncil® (remestemcel-L-rknd) generating US$36 million in net revenue during the June quarter, pushing the first full year post-FDA approval total to US$115 million. This performance underscores growing adoption of the stem cell therapy among US pediatric patients suffering from steroid-refractory acute graft versus host disease (SR-aGvHD), a life-threatening inflammatory condition.
The company is now aggressively pursuing label extensions beyond pediatric use. A pivotal registration trial for adults with SR-aGvHD, an addressable market roughly three times larger than the pediatric segment, has commenced across up to 40 US sites, targeting approximately 60% of the annual allogeneic adult bone marrow transplant population. This trial signals Mesoblast’s intent to broaden Ryoncil®’s commercial footprint.
Clinical Progress in Chronic Low Back Pain and Heart Failure
Mesoblast also announced the completion of patient enrollment in its MSB-DR004 Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain linked to degenerative disc disease. The trial hit its 300-patient target, with twelve-month endpoints set to assess pain reduction efficacy versus placebo. This trial represents a critical step toward addressing a potential multi-billion-dollar market.
On the regulatory front, the FDA has granted a Biologics License Application (BLA) filing number for rexlemestrocel-L aimed at preventing gastrointestinal bleeding in end-stage heart failure patients with left ventricular assist devices (LVAD). The company has requested a modular review to expedite assessment, reflecting strategic prioritisation of this niche but severe indication.
Financial Position Strengthened by Debt Refinancing
Financially, Mesoblast drew down an additional US$50 million from its existing five-year credit facility, bringing total drawn debt to US$125 million. This move allowed the company to extinguish all maturing debt obligations, including a senior debt facility with NovaQuest Capital Management, thereby streamlining its capital structure. At quarter-end, Mesoblast held US$103 million in cash, with net operating cash spend of US$43.8 million for the full fiscal year, reflecting disciplined capital management amid ongoing clinical and commercial investments.
Next-Generation Cell Therapy Platform via CAR Technology
Mesoblast unveiled a strategic acquisition of an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform. This innovation is designed to enhance the potency and precision of its mesenchymal stromal cell (MSC) therapies. The company plans to deploy CAR-MSCs engineered to target inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease, as well as autoimmune conditions like Lupus Nephritis, where durable immunomodulation is critical.
This technology acquisition positions Mesoblast at the forefront of next-generation cellular medicines, potentially unlocking new therapeutic avenues and commercial opportunities beyond its current portfolio.
Regulatory Advances in Pediatric Duchenne Muscular Dystrophy
The FDA has also cleared an Investigational New Drug (IND) application for a registrational trial of Ryoncil® in ambulatory children aged 5-9 years with Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting approximately 15,000 children in the US. This trial exemplifies Mesoblast’s commitment to expanding its pipeline into diverse, life-threatening inflammatory diseases.
Bottom Line?
Mesoblast’s solid revenue foundation and strategic investments in adult indications and CAR technology set the stage for potential growth inflection points, though clinical readouts and regulatory approvals remain key near-term catalysts.
Questions in the middle?
- How will adult SR-aGvHD trial enrolment and outcomes impact Ryoncil®’s market expansion?
- What clinical data will emerge from the chronic low back pain Phase 3 trial by mid-2027?
- Could the CAR technology platform materially enhance Mesoblast’s competitive position in autoimmune diseases?